These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37932204)

  • 1. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
    Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
    Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.
    Rebuzzi SE; Cerbone L; Signori A; Santoni M; Murianni V; De Giorgi U; Procopio G; Porta C; Milella M; Basso U; Massari F; Maruzzo M; Iacovelli R; Battelli N; Carmisciano L; Banna GL; Buti S; Fornarini G
    Ther Adv Med Oncol; 2022; 14():17588359221079580. PubMed ID: 35237353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
    Rebuzzi SE; Signori A; Buti S; Banna GL; Murianni V; Damassi A; Maruzzo M; Giannarelli D; Tortora G; Galli L; Rizzo M; De Giorgi U; Antonuzzo L; Bracarda S; Cartenì G; Atzori F; Tamberi S; Procopio G; Fratino L; Lo Re G; Santoni M; Baldessari C; Astone A; Calabrò F; Brunelli M; Porta C; Rescigno P; Basso U; Fornarini G
    ESMO Open; 2022 Dec; 7(6):100634. PubMed ID: 36493602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).
    Rebuzzi SE; Signori A; Banna GL; Maruzzo M; De Giorgi U; Pedrazzoli P; Sbrana A; Zucali PA; Masini C; Naglieri E; Procopio G; Merler S; Tomasello L; Fratino L; Baldessari C; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Stellato M; Atzori F; Pignata S; Messina C; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Pierantoni F; Casadei C; Bersanelli M; Chiellino S; Paolieri F; Perrino M; Brunelli M; Iacovelli R; Porta C; Buti S; Fornarini G
    Ther Adv Med Oncol; 2021; 13():17588359211019642. PubMed ID: 34046089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study.
    Rebuzzi SE; Signori A; Banna GL; Gandini A; Fornarini G; Damassi A; Maruzzo M; De Giorgi U; Basso U; Chiellino S; Galli L; Zucali PA; Fantinel E; Naglieri E; Procopio G; Milella M; Boccardo F; Fratino L; Pipitone S; Ricotta R; Panni S; Mollica V; Sorarù M; Santoni M; Cortellini A; Prati V; Soto Parra HJ; Santini D; Atzori F; Di Napoli M; Caffo O; Messina M; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Roviello G; Rescigno P; Buti S
    J Transl Med; 2022 Sep; 20(1):435. PubMed ID: 36180954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
    Rebuzzi SE; Fornarini G; Signori A; Buti S; Procopio G; De Giorgi U; Pignata S; Naglieri E; Maruzzo M; Banna GL; Rescigno P; Messina C; Mattana A; Basso U; Bimbatti D
    BMC Cancer; 2024 Jun; 24(1):757. PubMed ID: 38914928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
    Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
    Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
    Roviello G; Gambale E; Giorgione R; Santini D; Stellato M; Fornarini G; Rebuzzi SE; Basso U; Bimbatti D; Doni L; Nesi G; Bersanelli M; Buti S; De Giorgi U; Galli L; Sbrana A; Conca R; Carella C; Naglieri E; Pignata S; Procopio G; Antonuzzo L
    Cancer Med; 2022 Aug; 11(16):3084-3092. PubMed ID: 35312175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
    Santoni M; Aurilio G; Massari F; Grande E; Matrana MR; Rizzo M; De Giorgi U; Incorvaia L; Martignetti A; Molina-Cerrillo J; Zabalza IO; Mollica V; Rizzo A; Battelli N; Porta C
    Clin Genitourin Cancer; 2022 Jun; 20(3):285-295. PubMed ID: 35305916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
    Maruzzo M; Pierantoni F; Bortolami A; Palleschi D; Zivi A; Nicodemo M; Sartori D; De Vivo R; Zustovich F; Bimbatti D; Pastorelli D; Vultaggio GD; Soraru' M; Ballestrin M; Modonesi C; Randisi P; Barile C; Perri G; Basso U; Zagonel V
    Target Oncol; 2022 Jul; 17(4):467-474. PubMed ID: 35751733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
    Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib.
    Martini DJ; Kline MR; Liu Y; Shabto JM; Carthon BC; Russler GA; Yantorni L; Hitron EE; Caulfield S; Goldman JM; Harris WB; Kucuk O; Master VA; Bilen MA
    Cancer Treat Res Commun; 2021; 28():100393. PubMed ID: 34029879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
    Iacovelli R; Ciccarese C; Maruzzo M; Atzori F; Galli L; Scagliarini S; Massari F; Verzoni E; Cannella A; Maratta MG; Caserta C; Bimbatti D; Deppieri FM; Dessi M; Paolieri F; Riccardi F; Bracarda S; De Giorgi U; Basso U; Tortora G; Procopio G
    Clin Genitourin Cancer; 2022 Oct; 20(5):498.e1-498.e9. PubMed ID: 35768316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
    Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
    Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
    Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
    Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
    Vano YA; Phan L; Gravis G; Korakis I; Schlürmann F; Maillet D; Bennamoun M; Houede N; Topart D; Borchiellini D; Barthelemy P; Ratta R; Ryckewaert T; Hasbini A; Hans S; Emambux S; Cournier S; Braychenko E; Elaidi RT; Oudard S
    Int J Cancer; 2022 Oct; 151(8):1335-1344. PubMed ID: 35603906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis.
    Iacovelli R; Ciccarese C; Facchini G; Milella M; Urbano F; Basso U; De Giorgi U; Sabbatini R; Santini D; Berardi R; Santoni M; Bracarda S; Massari F; Masini C; De Tursi M; Ricotta R; Buti S; Zustovich F; Sepe P; Rossetti S; Maruzzo M; Cortesi E; Tortora G; Procopio G
    Target Oncol; 2020 Aug; 15(4):495-501. PubMed ID: 32671807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.